10-K: Wellgistics Health Reports $101M Loss, Nasdaq Delisting Risk

Wellgistics Health reported a significant net loss of $101.3 million for 2025, facing Nasdaq delisting concerns and substantial debt obligations.

Summary

• Reported a net loss of $101,274,530 for the year ended December 31, 2025, a substantial increase from a net loss of $6,856,226 in 2024.
• Net revenues increased to $23,337,860 in 2025 from $18,128,831 in 2024, primarily due to the full-year inclusion of acquired operations.
• Experienced a gross loss of $(6,426,419) in 2025, a significant decline from a gross profit of $1,767,314 in 2024, with gross margin falling to (27.5)% from 9.7%.
• General and administrative expenses surged to $70,332,827 in 2025, largely driven by $54,048,525 in non-cash stock-based compensation.
• Recognized a non-cash impairment charge of $12,554,266 related to goodwill and intangible assets from recent acquisitions.
• Received a Nasdaq deficiency letter on December 10, 2025, for failing to meet the minimum $1.00 bid price requirement, risking delisting by June 8, 2026.
• Total outstanding debt and credit obligations amounted to $23,487,520 as of December 31, 2025.
• Involved in litigation with former management regarding alleged breaches and misrepresentations, with approximately $17.5 million in associated liabilities recorded as of December 31, 2025.
• Management identified material weaknesses in internal control over financial reporting across multiple components of the COSO framework.
• Cash and cash equivalents decreased significantly to $42,571 at December 31, 2025, from $1,028,336 at December 31, 2024.
• Subsequent to year-end, raised aggregate gross proceeds of $9,000,000 from two private placements of convertible promissory notes in January 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly concerning report due to the massive net loss, negative gross margin, severe liquidity issues, Nasdaq delisting risk, and explicit going concern doubt, despite some revenue growth.

Positives

• Net revenues increased to $23,337,860 in 2025 from $18,128,831 in 2024, primarily due to the full-year inclusion of Wellgistics Pharmacy and Wellgistics Tech & Hub operations following acquisitions.
• Successfully completed an initial public offering on February 24, 2025, raising $4.0 million in gross proceeds and approximately $3.12 million in net proceeds.
• Wellgistics Pharmacy is licensed in 32 states and the District of Columbia, providing superb license coverage along the east coast and expanding service capabilities.
• Wellgistics LLC operates as a 50-state FDA licensed and NABP-accredited pharmaceutical wholesaler distributor, serving over 5,000 registered pharmacies nationwide.
• The DelivMeds technology platform is designed to serve as a pharmacy hub and provide clinical services, aiming to improve patient autonomy, prescription price transparency, and medication adherence.
• Obtained SOC-II Type 1 compliance on March 18, 2025, indicating a commitment to cybersecurity and data security standards.
• Subsequent to December 31, 2025, the company raised $9,000,000 in gross proceeds from two private placements of convertible promissory notes in January 2026, providing additional working capital.

Negatives

• Reported a substantial net loss of $101,274,530 for 2025, significantly wider than the $6,856,226 net loss in 2024.
• Gross profit turned into a gross loss of $(6,426,419) in 2025, with gross margin declining to (27.5)%, primarily due to liquidity constraints, higher inventory procurement costs, and delayed product shipments.
• Recognized a non-cash impairment charge of $12,554,266 related to goodwill and intangible assets, reflecting lower-than-expected future cash flows from acquired businesses.
• Liquidity constraints led to a $5,988,257 write-off of aged inventory and limited the ability to procure inventory efficiently, resulting in higher per-unit costs.
• Received a Nasdaq deficiency letter on December 10, 2025, due to the common stock's closing bid price falling below the minimum $1.00 per share, posing a risk of delisting.
• General and administrative expenses increased dramatically to $70,332,827 in 2025, largely due to $54,048,525 in non-cash stock-based compensation, including $24.3 million from accelerated vesting of the CEO's restricted shares.
• Total outstanding debt and credit obligations were $23,487,520 as of December 31, 2025, with interest expense of $4,579,556 in 2025.
• Incurred a total loss on debt extinguishment of $2,987,922 in 2025 due to refinancing and debt conversion activities.
• Management identified material weaknesses in internal control over financial reporting, indicating deficiencies in the control environment, risk assessment, control activities, information and communication, and monitoring.
• Engaged in litigation with former management over alleged breaches and misrepresentations, with approximately $17.5 million in associated liabilities.
• Received a demand letter on February 27, 2026, from Strategic EP, LLC, indicating a default on a $250,000 promissory note.
• Cash and cash equivalents decreased significantly from $1,028,336 at December 31, 2024, to $42,571 at December 31, 2025.
• Net cash used in operating activities was $(10,855,029) for the year ended December 31, 2025.
• Management explicitly stated that subsequent capital raises do not sufficiently alleviate the substantial doubt about the company's ability to continue as a going concern.

Risks

• Limited operating history as a combined company and evolving business make it difficult to evaluate current business and future prospects, increasing investment risk.
• May experience difficulties in integrating the operations of Wellgistics LLC and Wood Sage, hindering the realization of expected benefits from these transactions.
• Reductions in third-party reimbursement levels from private or governmental agency plans and potential changes in industry pricing benchmarks for prescription drugs could materially and adversely affect results of operations.
• A shift in pharmacy mix toward lower margin plans, margin compression on branded medications, increased offering of specialty products, direct and indirect remuneration (DIR) fees, and mail order pharmacy steering could adversely affect results of operations.
• Participation in the pharmacy provider networks of pharmacy benefit management (PBM) companies may be restricted or terminated, adversely affecting sales.
• Could be adversely affected by a decrease in the introduction of new brand name and generic prescription drugs, as well as increases in the cost to procure prescription drugs.
• Consolidation and strategic alliances in the healthcare industry could adversely affect business operations, competitive positioning, financial condition, and results of operations.
• Changes in economic conditions could adversely affect consumer/client buying practices and market adoption of the DelivMeds mobile application and associated revenues.
• Inflationary pressures could have a material impact on business and operations, particularly for the specialty-lite business segment ($500 $3,000 therapies).
• The industries in which the company operates are highly competitive and constantly evolving, and changes in market dynamics could adversely impact the company.
• Failure to successfully create and implement relevant omni-channel experiences for customers could adversely impact businesses and results of operations.
• May be unable to achieve environmental, social, and governance goals, negatively impacting public perception and talent retention.
• Business results depend on the ability to successfully manage ongoing organizational change and business transformation and achieve cost savings and operating efficiency initiatives.
• Disruption in the global supply chain could negatively impact businesses, including product procurement and delivery.
• Business and operations will be subject to risks related to climate change, such as increased costs for products, commodities, energy, and transportation.
• Business is primarily focused on certain therapeutic targets (specialty-lite), making it vulnerable to risks associated with therapeutically concentrated operations.
• Failure to retain and recruit, or failure to manage succession of, key personnel could have an adverse impact on future performance.
• Highly dependent on the continued service of directors and officers, whose financial interests may conflict with the interests of investors.
• Failure to renew facility leases in a timely manner could have an adverse impact on business operations.
• May not be able to maintain business, scale for growth, renew pharmacy and wholesale state licenses, and retain commercial and federal contracts while preventing restrictions and termination.
• Relationships with the primary wholesaler for pharmacy operations (AmerisourceBergen) and manufacturer relationships for wholesale and hub technology platform entities will be critical to success and are subject to termination risks.
• Outsourcing certain business processes to third-party vendors subjects the company to risks, including disruptions in business and increased costs.
• May not be successful in executing elements of its business strategy, which may have a material adverse impact on business and financial results.
• Growth strategy is partially dependent upon the ability to identify and successfully complete acquisitions, joint ventures, and other strategic partnerships and alliances.
• Businesses acquired could experience losses or liabilities, including medical liability claims, resulting in significant expenses.
• May make investments in companies over which it does not have sole control, subjecting it to additional operating and financial risks.
• The success of the hub technology platform and clinical services depends on the willingness of participants in the network of independent partner pharmacies to continue receiving prescriptions and enrolling in a-la-carte services.
• A significant disruption in information technology and computer systems or those of businesses relied on could harm the company.
• Privacy and data protection laws will increase compliance burden, and any failure to comply could harm the company.
• May experience cybersecurity incidents and significant computer system compromises or data breaches, leading to workflow disruption, reputational damage, and financial liabilities.
• Subject to electronic payment-related and other financial services risks that could increase operating costs, expose to fraud or theft, and disrupt business operations.
• Has significant outstanding debt, and associated payment obligations could significantly increase, negatively impacting liquidity and restricting operations.
• Quarterly results may fluctuate significantly based on seasonality and other factors, making quarter-to-quarter comparisons not necessarily meaningful.
• Has a substantial amount of goodwill and other intangible assets which could, in the future, become impaired and result in material non-cash charges to results of operations.
• Acquisitions could result in operating difficulties, dilution to stockholders, and other consequences harmful to the business.
• Level of debt may negatively impact liquidity, restrict operations and ability to respond to business opportunities, and increase vulnerability to adverse economic and industry conditions, especially with variable interest rates.
• Existing credit agreement and any other credit or similar agreements into which the company may enter in the future may restrict operations, particularly the ability to respond to changes or to take certain actions.
• Business is subject to substantial governmental regulation, including Anti-Kickback Statutes, Physician Self-Referral (Stark) Laws, False Claims Act, state licensure, and HIPAA.
• Will be exposed to risks related to litigation and other legal proceedings.
• A significant change in, or noncompliance with, governmental regulations and other legal requirements could have a material adverse effect on reputation and profitability.
• Could be adversely affected by product liability, product recall, personal injury, or other health and safety issues.
• Could be subject to adverse changes in tax laws, regulations, and interpretations or challenges to tax positions.
• Despite actions taken to defend and protect intellectual property, may not be able to adequately protect or enforce intellectual property rights or prevent unauthorized parties from copying or reverse engineering solutions.
• Third-party claims that the company is infringing intellectual property, whether successful or not, could subject it to costly and time-consuming litigation or expensive licenses.
• Intellectual property applications for registration may not issue or be registered, which may have a material adverse effect on the ability to prevent others from commercially exploiting similar products.
• Relies on unpatented proprietary technology, trade secrets, designs, experiences, work flows, data, processes, software, and know-how, which may be difficult to protect.
• May be subject to damages resulting from claims that it or its current or former employees have wrongfully used or disclosed alleged trade secrets of former employers.
• Incurs increased costs as a result of operating as a public company, and management will devote substantial time to compliance with public company responsibilities and corporate governance practices.
• Management team has limited experience managing a public company.
• Ability to be successful will depend upon the efforts of the board of directors and key personnel, and the loss of such persons could negatively impact operations and profitability.
• Delaware State Law includes anti-takeover provisions that could delay or prevent an acquisition.
• Claims for indemnification by directors and officers may reduce available funds to satisfy successful third-party claims.
• If securities or industry analysts do not publish or cease publishing research or reports about the company, its business, or its market, or if they change their recommendations adversely, the price and trading volume of securities could decline.
• There can be no assurance that common stock will be approved for listing on Nasdaq or, if approved, will continue to be so listed, or that the company will be able to comply with the continued listing standards of Nasdaq.
• Common stock may be subject to the penny stock rules, which may make it more difficult to sell.
• An active market for securities may not develop, which would adversely affect the liquidity and price of securities.
• The market price of common stock may decline as a result of various market factors.
• Future sales, or the perception of future sales, by the company or its stockholders in the public market could cause the market price for common stock to decline.
• Qualifies as an emerging growth company and a smaller reporting company, and taking advantage of certain exemptions from disclosure requirements may make securities less attractive to investors.
• Certain existing stockholders acquired securities at a price below the current trading price and may experience a positive rate of return, potentially leading to sales that adversely affect the market price.

Future Outlook

Management expects gross margin to improve as liquidity stabilizes and inventory purchasing normalizes in the upcoming years. The company anticipates potential partner relationships will enable its pharmacy business to offer a competitive cash formulary. It intends to expand wholesale activities by partnering with existing and establishing new manufacturer relationships, strategically identifying opportunities to wholesale products not normally carried by the three largest wholesalers. New partnerships with group purchasing organizations are expected to increase business visibility. The DelivMeds model is projected to generate recurring SaaS transaction fees from pharmaceutical manufacturers and strategic channel partners for various services and data access. DelivMeds plans to provide many clinical services virtually through its tele-pharmacy program in the near future. The company expects to generate positive cash flow from operations in 2025 (though actual results show otherwise for 2025). Long-term liquidity requirements include strategic acquisitions, expansion of micro-distribution centers, investments into artificial intelligence, machine learning, and data warehousing capabilities, and additional integrations with third-party partners. The company will continue to monitor investment activities and evaluate the impact of ASU 2023-08 should it acquire crypto assets in the future, and is evaluating the impact of ASU 2024-03 and ASU 2025-06, while not expecting a material impact from ASU 2025-05 or only disclosure impact from ASU 2025-11.

Management Comments

• Our management believes that our digital pharmacy business, hub and clinical services technology platform, and wholesale distribution operations will place us in a position to provide significant value in this key specialty-lite market by providing patients access and convenience, while providing partners with ready-to-go market solutions with big data.
• Our management believes that we will be in a prime position to address prescription spending in the specialty lite therapy area while improving patient health outcomes by equipping patients with innovative digital health tools.
• Wellgistics Pharmacy continues to see an uptick in utilization, as more patients elect to pay out of pocket due to our low-cost model, which Wellgistics Pharmacy believes is an opportunity to gain market share with smallto medium-size employer groups in a partnership model with other consumer driven healthcare companies.
• Our management believes DelivMeds digital pharmacy concept with hub services will be able to provide the following benefits to partner pharmacies who join the DelivMeds network: Streamlined Workflow, Increased Revenue, Larger Patient Diversification, and Additional Renumeration Opportunities.
• Our management believes that DelivMeds digital pharmacy concept with mobile technology is able to provide payors and PBMs with aggregate data to provide these additional benefits: Compliance (Programs), Compliance (Therapy), Compliance (Costs), Compliance (Transportation), and Reducing Expenses.
• Management expects gross margin to improve as liquidity stabilizes and inventory purchasing normalizes in the upcoming years.
• Management is working toward resolving the obligation and addressing the default under the terms of the agreement [with Strategic EP, LLC].
• Management has determined that the aforementioned plans [subsequent convertible note offerings] do not sufficiently alleviate the substantial doubt about the Companys ability to continue as a going concern through twelve months from the date these audited consolidated financial statements are issued.

Industry Context

StockSavvy.ai notes that the healthcare industry is undergoing significant transformation, characterized by increased managed care, cuts in government funding, and widespread consolidation among competitors and suppliers. The Inflation Reduction Act (IRA) of 2023 is directly impacting drug pricing and federal spending, creating a challenging environment for pharmaceutical companies. Wellgistics Health's focus on the specialty-lite drug market, which accounts for over 50% of prescription drug spend despite being less than 10% of total drugs, positions it in a high-value but competitive niche. The persistent challenge of poor medication adherence, leading to increased hospital admissions and healthcare costs, highlights the need for innovative solutions like Wellgistics Health's digital health tools. The broader trend of vertical integration among major players (e.g., CVS/Caremark, United Healthcare) and the rise of self-funded organizations are driving demand for pricing transparency and value-based care models, which Wellgistics Health aims to address with its integrated ecosystem. The digital pharmacy sector is also highly competitive, with numerous entrants leveraging telehealth and cash-paying models, requiring continuous innovation and differentiation.

Comparison to Industry Standards

• The U.S. market for medicines reached $435 billion in 2023, according to IQVIA's 2024 report, indicating a large but competitive market for Wellgistics Health's operations.
• National Health Expenditure Data for 2022 grew to $4.5 trillion, accounting for 17.3% of GDP, with an expected increase to 19.7% by 2032, highlighting the growing scale of the healthcare market Wellgistics Health operates within.
• The specialty drug market, which Wellgistics Health targets, accounts for less than 10% of total drugs but is responsible for greater than 50% of the prescription drug spend per annum, indicating a high-value segment.
• A 2019 study by NACDS found the overall cost of dispensing for all drugs was $12.40 per fill, estimated at $14.68 per fill after inflation, which Wellgistics Health's low-cost model aims to undercut for uninsured/underinsured patients.
• Wellgistics Health aims to achieve patient adherence rates greater than 80-90% based on Healthcare Effectiveness Data and Information Set (HEDIS), National Committee for Quality Assurance (NCQA), and Utilization Review Accreditation Commission (URAC) standards, which are widely recognized benchmarks for quality in healthcare.
• The company's network of independent pharmacies represents over 19,000 pharmacies across the United States, servicing 1.3 billion prescriptions annually, representing a $47 billion market at wholesale cost, demonstrating significant market reach.
• The hub technology platform's partnership with Best Rx pharmacy software system, utilized by approximately 1,400 independent pharmacies (over 6% of the independent pharmacy market share), provides a foundation for its integrated network.
• Management's relationships with PrimeRx MARKET and Pioneer Rx could provide access to more than 16,500 pharmacies, accounting for 87% of the independent Pharmacy Management Software (PMS) market, indicating potential for significant network expansion.
• Integrations with national ride-sharing logistics providers like Lyft Healthcare, Inc. and Roadie, alongside major shipping carriers (USPS, UPS, FedEx), position Wellgistics Health to offer competitive same-day and next-day prescription delivery services, aligning with evolving consumer expectations for convenience.

Management Changes

Corporate Governance

Legal Proceedings

• Litigation initiated on October 10, 2025, against certain former officers and/or directors (Former Management Parties) in Florida Circuit Court, asserting claims including breach of fiduciary duty of loyalty, breach of contract, and tortious interference. Defendants filed a motion to compel arbitration on December 10, 2025, which the Company opposes, with a hearing scheduled for April 27, 2026.
• In January 2026, served notice of claims against Former Management Parties for misrepresentations and omissions related to an acquisition, seeking rescission and cancellation of equity awards and related remedies. Obligations associated with these arrangements are reflected as liabilities of approximately $17.5 million as of December 31, 2025.
• A demand for arbitration was filed on August 21, 2024, by Blythe Global Advisors, LLC against the Company and the Chairman of the Board for breach of contract and personal guaranty, claiming $377,947 for unpaid accounting services.
• Company subsidiaries (Wellgistics, LLC, Wood Sage, LLC, Alliance Pharma Solutions, LLC, and Community Specialty Pharmacy, LLC) sued Blythe Global Advisors, LLC in early 2025 for improper UCC-1 filings, tortious interference, slander of title, and state RICO violations, claiming the filing impeded credit line access.
• Wellgistics, LLC is a defendant in a legal proceeding initiated by Lifsa Drugs LLC in the United States District Court for the District of New Jersey for alleged failure to pay for pharmaceutical products, seeking approximately $420,460 plus interest and fees.
• Received demand letters from various vendors requesting payment for approximately $2.2 million for goods and services, with $1.5 million already recorded as accounts payable and $0.7 million not recorded as a loss is not probable.

Related Party Transactions

• Transactions with Scienture Holdings, Inc. (f/k/a TRxADE Health, Inc.) and group, including Integra Pharma Solutions, LLC (IPS), where board members of the Company were also members of Scienture's management and board.
• Purchased $500,000 of inventories from Tollo Health, LLC during the first quarter of 2025, which was a related party until June 2025.
• Outstanding indebtedness of $4,019,859 to Integra Pharma Solutions, LLC was converted into 5,742,656 shares of common stock on October 30, 2025.
• Outstanding indebtedness of $1,300,000 to Integral Health Inc. was converted into 1,857,143 shares of common stock on October 30, 2025.
• Wellgistics, LLC had transactions with affiliated companies of Nomad Capital LLC (a previous owner of Wellgistics LLC), including software and marketing expenses.
• IT Support fees were paid to Scietech, LLC, where a significant investor is the spouse of one of the Company's directors.
• IT expenses were paid to Cingo Solutions and Birch OS & RxERP.
• Management services fees were paid to Nomad Capital.
• Business development and consultation fees were paid to Green Apoteker LLC.
• Due from related parties (TRG, IPS, Scienture Holdings) decreased from $1,021,000 at December 31, 2024, to $0 at December 31, 2025.
• Due to related parties (CEO, TRG, IPS, Scienture Holdings) decreased from $4,944,770 at December 31, 2024, to $225,000 (due to CEO) at December 31, 2025.
• Sales to Integra Pharma Solutions, LLC were $746,728 in 2024 and $220,820 in 2025 (before it ceased being a related party).
• An April 2025 Promissory Note for $500,000 was issued to Sansur Associates, LLC (beneficially owned by Chairman Suren Ajjarapu), but no funds were advanced, and the note was mutually terminated in August 2025.

Stakeholder Impact

• Shareholders face significant dilution from multiple equity issuances (IPO, public offering, debt conversions, stock-based compensation) and the substantial net loss, which has led to a negative stockholders' equity. The Nasdaq delisting notice poses a severe risk to liquidity and market price, while ongoing litigation and explicit going concern doubt threaten the long-term value of their investment.
• Employees may experience uncertainty due to frequent management changes (CEO, CFO, directors) and the company's overall financial instability. While executive compensation includes substantial stock-based awards, the company's precarious financial position could impact job security and future compensation for other employees.
• Customers, including pharmacies, providers, and patients, could be affected by the company's liquidity constraints, which have caused delays in product shipments and higher procurement costs, potentially impacting product availability and pricing. The success of the DelivMeds platform in improving patient autonomy, price transparency, and adherence is dependent on the company's ability to maintain and expand its network and technology integrations amidst financial challenges.
• Suppliers and creditors face heightened payment risks, as evidenced by the company's liquidity constraints, default on a promissory note with Strategic EP, LLC, and ongoing litigation with vendors like Lifsa Drugs LLC and Blythe Global Advisors, LLC over unpaid invoices. The company's ability to meet its debt obligations and manage accounts payable is a significant concern.
• Regulatory bodies may increase scrutiny due to the identified material weaknesses in internal control over financial reporting, ongoing litigation, and the Nasdaq delisting notice. Non-compliance with various healthcare and securities regulations could lead to further penalties and operational restrictions.

Next Steps

• Regain compliance with Nasdaq's minimum $1.00 bid price requirement by June 8, 2026, potentially through a reverse stock split.
• Attend a hearing on April 27, 2026, for a motion to compel arbitration in litigation against former management.
• Continue evaluating litigation with former management and adjust related liabilities as appropriate.
• Resolve the default on the $250,000 promissory note with Strategic EP, LLC.
• Work towards stabilizing liquidity and normalizing inventory purchasing to improve gross margin.
• Implement measures to remediate material weaknesses in internal control over financial reporting, including hiring additional accounting personnel, enhancing review procedures, providing training, and upgrading to NetSuite ERP.
• Commence amortization of the Datavault AI Inc. licensed technology in 2026 once placed into service.
• Collaborate with Kare PharmTech LLC to commercialize the KARE Verify product through distribution and pharmacy networks.
• Continue to pursue opportunities to broaden and diversify the customer base to reduce concentration risk.
• Identify strategic partners within the Best Rx network and other PMS systems (Prime Rx, Pioneer Rx, Liberty, Transactional Data Systems, Digital Business Solutions) to expand the integrated pharmacy network.
• Maintain ongoing relationships with ride-sharing logistics providers (Lyft Healthcare, Roadie) and shipping carriers (USPS, UPS, FedEx).
• Partner with Group Purchasing Organizations (GPOs) to onboard larger cohorts of pharmacies.
• Actively monitor the drug pipeline and maintain dialogue with biotechnology and pharmaceutical manufacturers to identify new product opportunities.

Key Dates

Recommendation

The company reported a massive net loss of over $101 million, a negative gross margin, and critically low cash reserves, raising substantial doubt about its ability to continue as a going concern. The Nasdaq delisting notice, significant impairment charges, and ongoing litigation with former management further compound the severe financial and operational distress. While recent capital raises provide some short-term relief, management explicitly states they do not alleviate the going concern doubt. These factors indicate extreme risk and a high probability of further value erosion, making it a strong sell for investors.

Keywords

Pharmaceuticals, Healthcare Services, Pharmacy, Wholesale Distribution, Digital Health, DelivMeds, Wellgistics, SEC Filing, 10-K, Financial Report, Nasdaq, Stock-based Compensation, Impairment, Debt, Litigation, Corporate Governance, Risk Factors, Supply Chain, Regulatory Compliance, Intellectual Property, Going Concern